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Summary
Background: Myocardial ﬁbrosis is the major factor that regulates left ventricular
(LV) diastolic function. Pioglitazone, an anti-diabetic drug, is reported to improve the
LV diastolic function in diabetic patients, but its inﬂuence on myocardial ﬁbrosis has
not been clariﬁed. We evaluated the effect of pioglitazone on LV diastolic function
and myocardial ﬁbrosis in type 2 diabetic (T2DM) patients.
Methods and results: Fifteen T2DM patients were enrolled in the ON group,
and the parameters were examined before and after pioglitazone administration
(15—30mg/day) for 6 months. Twenty-four T2DM patients were assigned to the
OFF group, and the parameters were examined before and 6 months after ces-
sation of pioglitazone. We measured echocardiographic parameters such as early
diastolic mitral annular velocity (E′) and plasma concentration of aminoterminal
propeptide of procollagen type III (PIIIP), a marker of myocardial ﬁbrosis. In the ON
′group, pioglitazone signiﬁcantly increased E (6.04± 1.70 cm/s vs. 6.51± 1.64 cm/s,
p < 0.01) and decreased PIIIP (0.553± 0.056U/ml vs. 0.517± 0.072U/ml, p < 0.05).
There was a signiﬁcant negative correlation between the change in PIIIP and the
change in E′ (r =−0.424, p = 0.046). On the other hand, E′ was signiﬁcantly decreased
(5.69± 1.34 cm/s vs. 4.97± 1.20 cm/s, p < 0.01) in the OFF group. PIIIP was not
signiﬁcantly changed in the OFF group, but there was a signiﬁcant negative cor-
relation between the change in PIIIP and the change in E′ (r =−0.374, p = 0.035).
∗ Corresponding author. Tel.: +81 18 829 5000; fax: +81 18 829 5255.
E-mail address: gterui@archosp-1998.com (G. Terui).
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Conclusion: Six months of pioglitazone administration suppressed the synthesis of
type III collagen, and this was associated with improved LV diastolic function in T2DM
patients. Cessation of pioglitazone weakened the suppression of the synthesis of type
III collagen, which in turn seemed to be associated with worse LV diastolic function.
© 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
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ntroduction
he thiazolidine derivative pioglitazone, a per-
xisome proliferator-activated receptor (PPAR)-
gonist, is currently used as an anti-diabetic drug.
t is reported to have a variety of actions in addition
o a hypoglycemic action and an ameliorating effect
n insulin resistance. Improvement of abnormal
ipid metabolism, an anti-inﬂammatory effect, an
nti-atherogenic action, and an inhibitory effect on
xidative stress have been reported. With respect
o the heart, it was reported to inhibit myocar-
ial cell hypertrophy in rats [1], inhibit myocardial
brosis in a rat model of diabetes [2], inhibit
rogression of human coronary artery atheroscle-
osis [3], and inhibit recurrence of cardiovascular
vents [4]. We previously reported that pioglita-
one improved left ventricular diastolic function
n type 2 diabetic patients [5]. Myocardial ﬁbrosis
s the major factor that regulates left ventric-
lar diastolic function. Moreover, it has been
eported that a relationship was observed between
minoterminal propeptide of procollagen type III
PIIIP), a marker of myocardial ﬁbrosis, and heart
ailure in humans [6—9]. The purpose of the present
tudy is to investigate how left ventricular diastolic
unction and PIIIP change as a result of initiation
f oral administration of pioglitazone and discon-
inuation of oral administration in type 2 diabetic
atients.
ethods
ubjects and study protocol
e studied 15 patients with type 2 diabetes in
he ON group (8 men and 7 women; mean age,
7.8 years) and 24 patients with type 2 diabetes
n the OFF group (12 men and 12 women; mean
ge, 67.2 years). Patients were excluded if they
ad heart failure, left ventricular systolic fail-
re, moderate-to-severe valvular disease, atrial
brillation, liver dysfunction, collagen disease,
enal failure, pulmonary ﬁbrosis, or osteoporosis.
S
D
(
iuring this study, the doses of neither anti-
ypertensive drugs nor anti-diabetic drugs were
hanged. Informed consent was obtained from all
atients before participation in the study, and the
rotocol was approved by the Human Investigations
ommittee of our institution. Parameters were
xamined before and after pioglitazone administra-
ion (15—30mg/day) for 6 months in the ON group,
nd they were examined before and 6 months after
essation of pioglitazone in the OFF group.
chocardiography
-mode echocardiography and two-dimensional
maging were performed using a cardiac ultra-
ound unit (SONOS 5500; Hewlett Packard, Andover,
A, USA) in a blinded fashion before and after
reatment. Each patient was examined in the left
ateral decubitus position. Measurements included
eft ventricular ejection fraction (LVEF) calculated
sing Teichholtz’s formula, left ventricular Tei index
LVTEI) [10], and left ventricular mass index (LVMI)
11]. Assessment of early diastolic mitral annu-
ar velocity (E′) was performed by pulsed wave
issue Doppler imaging of the septal wall in api-
al 4-chamber view. Doppler echocardiogram was
ecorded at a sweep of 50mm/s and the mean
alue of three cardiac cycles was obtained. After
easurement of cardiac parameters, blood pres-
ure at the brachial artery and body weight were
easured.
lasma sample measurements
lood samples were collected from an antecu-
ital vein in the supine position before and after
months of treatment. Plasma PIIIP level was
easured with a speciﬁc immunoradiometric assay
sing a commercial kit (CIS Bio International,tatistical analysis
ata are expressed as mean± standard deviation
S.D.). Paired t-test was used for comparison of
ntragroup data. Linear regression analysis was used
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Table 1 Baseline clinical characteristics.
ON group (n = 15) OFF group (n = 24)
Gender (M/F) 8/7 12/12
Age (years) 67.8± 12.9 67.2± 7.0
HT treatment 6 (40.0) 13 (54.2)
ACEI or ARB 3 (20.0) 7 (29.2)
DM treatment 14 (93.3) 21 (87.5)
SU 4 (26.7) 9 (37.5)
BG 10 (66.6) 15 (62.5)
GI 4 (26.7) 4(16.7)
Insulin 3 (20.0) 5 (20.8)
Known DM duration (years) 9.5± 9.1 13.2± 6.6
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oValues are n (%), or mean± S.D. HT, hypertension; ACEI, ang
receptor blockers; DM, diabetes mellitus; SU, sulfonylurea age
to determine the relationship between continuous
variable. A p-value <0.05 was regarded as signiﬁ-
cant.
Results
On enrollment in the study, 6 patients in the ON
group and 13 patients in the OFF group were treated
for hypertension. Of those, 3 and 7 patients,
respectively, were taking angiotensin-converting
enzyme inhibitors or angiotensin II type I receptor
blockers. Fourteen and 21 patients, respectively,
were taking anti-diabetic drugs other than piogli-
tazone. The breakdown of anti-diabetic drugs that
were taken was as follows: a sulfonylurea agent in
4 and 9 patients, a biguanide agent in 10 and 15
patients, an alpha-glucosidase inhibitor in 4 and 4
patients, and insulin in 3 and 5 patients, respec-
tively. The duration of diabetes was 9.5± 9.1 and
13.2± 6.6 years, respectively (Table 1).
In the ON group, no signiﬁcant change in heart
rate or body weight was observed, and mean blood
pressure (mBP) decreased signiﬁcantly (93.2±
6.6mmHg vs. 89.1± 6.4mmHg (mean± S.D.),
p < 0.05). Hemoglobin A1c (HbA1c) decreased
signiﬁcantly (7.8± 1.0% vs. 6.9± 0.7%, p < 0.01).
Brain natriuretic peptide (BNP) was unchanged
(31.7± 41.3 pg/ml vs. 29.2± 46.6 pg/ml). Creati-
nine was unchanged (0.59± 0.17mg/dl vs. 0.63±
0.18mg/dl). Urinary albumin excretion (U-Alb)
was unchanged (38.9± 46.6mg/gCr vs. 39.7±
50.2mg/gCr). PIIIP decreased signiﬁcantly (0.553±
0.056U/ml vs. 0.517± 0.072U/ml, p < 0.05). LVEF
was unchanged (0.66± 0.60 vs. 0.66± 0.56), LVMI
was unchanged (120.2± 23.9 g/m2 vs. 121.1±
21.4 g/m2), and LVTEI decreased signiﬁcantly
(0.446± 0.114 vs. 0.382± 0.086, p < 0.01). E′
t
c
k
a
asin-converting enzyme inhibitors; ARB, angiotensin II type 1
G, biguanide agent; GI, alpha-glucosidase inhibitor.
ncreased signiﬁcantly (6.04± 1.70 cm/s vs. 6.51±
.64 cm/s, p < 0.01) (Table 2). Moreover, a neg-
tive correlation was seen between change in
IIIP (%PIIIP) and change in E′ (%E′) (r =−0.424,
= 0.046) (Fig. 1). Furthermore, there was no cor-
elation between change in mean blood pressure
%mBP) and change in E′ (%E′) (Fig. 2) or between
hange in HbA1c (%HbA1c) and change in E′ (%E′)
Fig. 3).
The mean duration of exposure to oral piogli-
azone in the OFF group was 16.9 months.
o signiﬁcant change in heart rate, mBP, body
eight, BNP, creatinine, U-Alb, HbA1c, PIIIP, LVEF,
r LVMI was observed. LVTEI increased signiﬁ-
antly (0.371± 0.083 vs. 0.439± 0.098, p < 0.01).
′ decreased signiﬁcantly (5.69± 1.34 cm/s vs.
.97± 1.20 cm/s, p < 0.01) (Table 3). Moreover, a
egative correlation was seen between change in
IIIP (%PIIIP) and change in E′ (%E′) (r =−0.374,
= 0.035) (Fig. 1). Furthermore, there was no cor-
elation between change in mean blood pressure
%mBP) and change in E′ (%E′) (Fig. 2) or between
hange in HbA1c (%HbA1c) and change in E′ (%E′)
Fig. 3).
iscussion
n addition to a hypoglycemic action, pioglita-
one, an oral anti-diabetic drug, is reported to
ave an anti-atherogenic action and an anti-
nﬂammatory effect [12], and it is reported to lower
xidative stress and left ventricular collagen con-
ent [13], in animal experimental models. Using
ardiomyocyte- and macrophage-speciﬁc PPAR
nockout mice, PPAR ligand pioglitazone could
ttenuate angiotensin II-induced cardiac ﬁbrosis by
ttenuating monocyte inﬂammatory behavior and
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Table 2 Changes in several variables before and after pioglitazone treatment in the ON group.
ON group Before After p-Value
Heart rate (beats/min) 69.0 ± 12.6 69.5 ± 14.3 NS
mBP (mmHg) 93.2 ± 6.6 89.1 ± 6.4 <0.05
Body weight (kg) 66.8 ± 18.2 67.7 ± 19.1 NS
Biochemical markers
BNP (pg/ml) 31.7 ± 41.3 29.2 ± 46.6 NS
Creatinine (mg/dl) 0.59 ± 0.17 0.63 ± 0.18 NS
U-Alb (mg/gCr) 38.9 ± 46.6 39.7 ± 50.2 NS
Hemoglobin A1c (%) 7.8 ± 1.0 6.9 ± 0.7 <0.01
PIIIP (U/ml) 0.553 ± 0.056 0.517 ± 0.072 <0.05
Echocardiography
LVEF 0.66 ± 0.60 0.66 ± 0.56 NS
LVMI (g/m2) 120.2 ± 23.9 121.1 ± 21.4 NS
LVTEI 0.446 ± 0.114 0.382 ± 0.086 <0.01
E′ (cm/s) 6.04 ± 1.70 6.51 ± 1.64 <0.01
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PValues are mean± S.D. mBP, mean blood pressure; BNP, brain
creatinine; PIIIP, aminoterminal propeptide of procollagen typ
mass index; LVTEI, left ventricular Tei index; E′, early diastolic
y inhibiting myocardial macrophage inﬁltration
14]. This action of PPAR ligands may be an adjunct
herapy to renin—angiotensin—aldosterone system
nhibition, but these putative anti-inﬂammatory
ardiac actions of PPAR need to be conﬁrmed
n humans. In humans, it is reported to have
owered intima-media complex thickness of the
arotid artery [15] and to have exhibited an anti-
therogenic action/anti-inﬂammatory effect [16].
ioglitazone was expected to improve heart func-
ion given its potential vasodilatory effect [17]. A
a
i
p
[
igure 1 Correlation between change in aminoterminal prop
iastolic mitral annular velocity (%E′) in the ON group (left)
IIIP/pretreatment value. %E′ = post-treatment of value of E′/iuretic peptide; U-Alb, urinary albumin excretion; Cr, serum
LVEF, left ventricular ejection fraction; LVMI, left ventricular
al annular velocity.
arge-scale observational study showed that thia-
olidine derivatives and metformin improved the
verall mortality rate of elderly patients with a his-
ory of diabetes and heart failure as compared with
ther anti-diabetic drugs and insulin [18]. In addi-
ion, it was reported that metformin improved the
rognosis of heart failure patients with diabetes
s compared with sulfonylurea [19], and that it
nhibited onset of cardiovascular events in diabetic
atients with a history of macrovascular disease
4]. In all of the above cases, it can be said that
eptide of procollagen type III (%PIIIP) and change in early
and OFF group (right). %PIIIP = post-treatment value of
pretreatment value.
56 G. Terui et al.
Figure 2 Correlation between change in mean blood pressure (%mBP) and change in early diastolic mitral annular
velocity (%E′) in the ON group (left) and OFF group (right). %mBP =post-treatment value of mean blood pres-
sure/pretreatment value. %E′ = post-treatment of value of E′/pretreatment value.
Figure 3 Correlation between change in hemoglobin A1c (%HbA1c) and change in early diastolic mitral annular velocity
(%E′) in the ON group (left) and OFF group (right). %HbA1c = post-treatment value of hemoglobin A1c/pretreatment
value. %E′ = post-treatment value of E′/pretreatment value.
Table 3 Changes in several variables before and after pioglitazone treatment in the OFF group.
OFF group Before After p-Value
Heart rate (beats/min) 65.5 ± 9.2 66.9 ± 9.9 NS
mBP (mmHg) 90.3 ± 7.2 89.7 ± 7.1 NS
Body weight (kg) 67.9 ± 13.6 66.9 ± 13.6 NS
Biochemical markers
BNP (pg/ml) 31.3 ± 25.1 35.0 ± 26.1 NS
Creatinine (mg/dl) 0.75 ± 0.30 0.77 ± 0.33 NS
U-Alb (mg/gCr) 32.0 ± 39.4 35.2 ± 50.9 NS
Hemoglobin A1c (%) 6.8 ± 0.7 7.0 ± 0.6 NS
PIIIP (U/ml) 0.591 ± 0.103 0.601 ± 0.081 NS
Echocardiography
LVEF 0.63 ± 0.08 0.63 ± 0.09 NS
LVMI (g/m2) 125.0 ± 24.5 124.9 ± 25.4 NS
LVTEI 0.371 ± 0.083 0.439 ± 0.098 <0.01
E′ (cm/s) 5.69 ± 1.34 4.97 ± 1.20 <0.01
Values are mean± S.D. mBP, mean blood pressure; BNP, brain natriuretic peptide; U-Alb, urinary albumin excretion; Cr, serum
creatinine; PIIIP, aminoterminal propeptide of procollagen type III; LVEF, left ventricular ejection fraction; LVMI, left ventricular
mass index; LVTEI, left ventricular Tei index; E′, early diastolic mitral annular velocity.
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Cffect of pioglitazone on left ventricular diastolic f
mprovement of insulin resistance led to the out-
ome of an improved prognosis in patients with
eart failure. Given these ﬁndings, while reten-
ion of water in the body was a known adverse
rug reaction [20], direct effects on the heart like
hose mentioned above were expected. Therefore,
e investigated the effect of pioglitazone on left
entricular diastolic function using echocardiogra-
hy, and we reported that pioglitazone improved
eft ventricular diastolic function in type 2 diabetic
atients [5]. In the present study, we investigated
he association between left ventricular diastolic
unction, as measured by echocardiography, and
IIIP, a marker of myocardial ﬁbrosis, at initiation
f oral administration of pioglitazone and after dis-
ontinuation of administration, to elucidate the
echanism.
Type III collagen is the primary constituent of the
yocardial collagen matrix. It is produced by car-
iac ﬁbroblasts [21] and is responsible for structural
aintenance of elastic organs [22]. PIIIP is consid-
red to be an indicator of type III collagen synthesis.
IIIP levels reﬂect the degree of myocardial ﬁbro-
is in dilated cardiomyopathy patients [6], chronic
eart failure patients [7], and recent myocardial
nfarction patients [8], and it is reported to be
ssociated with cardiac function or vital progno-
is. Moreover, it is reported that intramyocardial
ollagen turnover is associated with the severity
f dilated heart failure [9]. Therefore, we mea-
ured PIIIP as an indicator of myocardial ﬁbrosis.
he plasma PIIIP level in healthy subjects was
.496± 0.074U/ml (n = 18, age 66.4± 13.5 years),
hich was signiﬁcantly lower than that in patients
n the ON group and OFF group. In the present study,
hich included diabetic patients with or without
ypertension, it could be surmised that myocardial
brosis had progressed relative to baseline in both
roups.
Compared to non-diabetic patients, more dia-
etic patients suffer from ischemic heart disease
nd abnormal left ventricular function. Multi-
etector computed tomography with coronary
ngiography has been reported to be useful,
s a non-invasive clinical modality for ischemic
eart disease [23]. Echocardiography is chieﬂy
sed for detecting abnormal left ventricular func-
ion. E′ was used to represent left ventricular
iastolic function. This is calculated as early dias-
olic mitral annular velocity using pulsed wave
issue Doppler imaging. It is a non-invasive modal-
ty that uses echocardiography. It is said to
e less susceptible to the effects of preloading
24].
In the ON group, since mean baseline E′ was
.04 cm/s, which was low, and LVTEI was 0.446,
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hich exceeded the upper limit of normal, we con-
rmed that the type 2 diabetic patients enrolled
n this study suffered from decreased left ventricu-
ar diastolic function even though left ventricular
ystolic function was within the normal range.
nitiation of oral administration of pioglitazone
esulted in a signiﬁcant increase in E′, while LVEF
as unchanged and LVTEI decreased signiﬁcantly.
herefore, it was concluded that left ventricu-
ar diastolic function improved. Furthermore, since
IIIP decreased signiﬁcantly, and since a negative
orrelation was seen between change in PIIIP and
hange in E′, the improvement in left ventricu-
ar diastolic function was considered to be via an
nhibitory effect on myocardial ﬁbrosis. In addi-
ion, mBP and HbA1c decreased signiﬁcantly, but
o correlation was observed between change in
BP and change in E′, or between change in HbA1c
nd change in E′. Therefore, we determined that
he improvement in left ventricular diastolic func-
ion was not associated with a pioglitazone-induced
ecrease in blood pressure or decrease in blood
lucose.
In the OFF group, discontinuation of oral admin-
stration of pioglitazone resulted in a signiﬁcant
ecrease in E′, while LVEF was unchanged and LVTEI
ncreased signiﬁcantly. Therefore, it was concluded
hat left ventricular diastolic function deterio-
ated. PIIIP did not change signiﬁcantly, but a
egative correlation was observed between change
n PIIIP and change in E′. Accordingly, discontinu-
tion of oral administration of pioglitazone might
ave resulted in deterioration of left ventricular
iastolic function after attenuation of its inhibitory
ffect on myocardial ﬁbrosis. In addition, since no
orrelation was observed between change in mBP
nd change in E′, or between change in HbA1c and
hange in E′, we concluded that the improvement
n left ventricular diastolic function was not associ-
ted with a pioglitazone-induced change in blood
ressure or change in blood glucose. An associa-
ion between the rate of progression of myocardial
brosis due to aging and diabetes and the rate of
nset/cessation of the inhibitory effect of piogli-
azone on myocardial ﬁbrosis might have affected
IIIP levels, which showed no signiﬁcant difference.
signiﬁcant difference in PIIIP might have been
bsent due to the small sample size.
onclusionix months of pioglitazone administration sup-
ressed the synthesis of type III collagen, and this
as associated with improved left ventricular dias-
olic function in type 2 diabetic patients. And
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[
[
[
[
[
[
[
[
[
[
[58
cessation of pioglitazone weakened the suppression
of the synthesis of type III collagen, which in turn
seemed to be associated with worse left ventricular
diastolic function.
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